748 Ustekinumab Improved Work Productivity in Patients With Moderate to Severe Ulcerative Colitis: Results From the Phase 3 UNIFI Induction and Maintenance Studies
Chenglong Han(Janssen (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Colleen Marano(Johnson & Johnson (United States)), Dominik Naessens(Janssen (Belgium)), Jewel Johanns(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k